BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34527431)

  • 21. High
    Li XF; Zhang HB; Huo Y
    J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
    Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
    J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity.
    Liu S; Liu Y; Ma J; Lv R; Wang F
    Medicine (Baltimore); 2023 Sep; 102(35):e34851. PubMed ID: 37657028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omental Macrophagic "Crown-like Structures" Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer.
    Liang YL; Lin CN; Tsai HF; Wu PY; Lin SH; Hong TM; Hsu KF
    Curr Oncol; 2021 Oct; 28(5):4234-4246. PubMed ID: 34677277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumour-infiltrating lymphocytes.
    Yao J; Xi W; Chen X; Xiong Y; Zhu Y; Wang H; Hu X; Guo J
    Scand J Immunol; 2021 Apr; 93(4):e13006. PubMed ID: 33275792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
    Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
    Front Immunol; 2020; 11():89. PubMed ID: 32184777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
    Kim SI; Hwangbo S; Dan K; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
    Mol Cell Proteomics; 2023 Mar; 22(3):100502. PubMed ID: 36669591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
    Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
    Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
    [No Abstract]   [Full Text] [Related]  

  • 30. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
    Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
    Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
    Zhang H; Wu Y; Li H; Sun L; Meng X
    Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
    van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
    Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
    Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
    Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis.
    Su H; Jin Y; Tao C; Yang H; Yang E; Zhang WG; Feng F
    J Gynecol Oncol; 2023 Jul; 34(4):e48. PubMed ID: 36998223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
    Liu R; Hu R; Zeng Y; Zhang W; Zhou HH
    EBioMedicine; 2020 Jan; 51():102602. PubMed ID: 31911269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
    Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
    Cai D; Liu T; Fang J; Liu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.